mdm2 gene amplification is associated with luminal breast cancer progression in humanized PDX mice and a worse outcome of estrogen receptor positive disease

URN to cite this document:: urn:nbn:de:bvb:355-epub-513523
DOI to cite this document:: 10.5283/epub.51352

Wege, Anja Kathrin ; Rom‐Jurek, Eva‐Maria ; Jank, Paul ; Denkert, Carsten ; Ugocsai, Peter ; Solbach, Christine ; Blohmer, Jens‐Uwe ; Sinn, Bruno ; Mackelenbergh, Marion ; Möbus, Volker ; Trumpp, Andreas ; Marangoni, Elisabetta ; Pfarr, Nicole ; Irlbeck, Christoph

; Warfsmann, Jens ; Polzer, Bernhard

; Weber, Florian ; Ortmann, Olaf

; Loibl, Sibylle ; Vladimirova, Valentina ; Brockhoff, Gero

Preview

License: Creative Commons Attribution Non-commercial No Derivatives 4.0
PDF - Published Version
Early View
(11MB)

Date of publication of this fulltext: 11 Jan 2022 07:17

Alternative links to fulltext:DOI Publisher

This publication is part of the DEAL contract with Wiley.

Details

Preview: Early View

Indexed in

Export bibliographical data

Abstract

Estrogen receptor-positive breast cancer is a highly prevalent but heterogeneous disease among women. Advanced molecular stratification is required to enable individually most efficient treatments based on relevant prognostic and predictive biomarkers. First objective of our study was the hypothesis-driven discovery of biomarkers involved in tumor progression upon xenotransplantation of Luminal ...